Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
Journal: Journal of Parkinson's disease
Published: August 05, 2017
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Journal: JAMA neurology
Published: June 13, 2017
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: March 02, 2017
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: June 19, 2014
Showing 1-4 of 4
Last Updated: 09/26/2026